Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.
FDA Approves Alectinib for Early-Stage ALK+ NSCLC
The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.
Achieving Health Equity in Lung Cancer Surgery
Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.
VGT-309 Helps Visualize Tumors During Robotic-Assisted Lung Cancer Surgery
Results from a phase 2 trial support the safety and tolerability of VGT-309 in patients with suspected lung cancer who undergo standard-of-care surgical resection.
Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC
Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.
New Lung Cancer Treatment Options Combine Neoadjuvant and Adjuvant Therapies
Misako Nagasaka, MD, PhD, sheds light on neoadjuvant and adjuvant treatment options for patients with lung cancer.
Key Data Overview in NSCLC From ESMO 2023
During the European Society for Medical Oncology 2023, experts discussed updated results in key trials across the lung cancer space.